The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
- DRUG: Donafeinib
- PROCEDURE: Transcatheter arterial chemoembolization
- DRUG: PD-1 / PD-L1 monoclonal antibody
- PROCEDURE: Hepatic Artery Infusion Chemotherapy
Sponsor
Shanghai Zhongshan Hospital
Collaborators